Nicox Completes Key Data for NCX 470 NDA Filing in US and China
Nicox completes all data for NCX 470, a glaucoma therapy, ahead of 2026 U.S. and China NDA filings, positioning its eye‑care pipeline for regulatory approval.
2 minutes to read
Nicox
Nicox Advances Ophthalmic Therapies with Vyzulta, NCX 470 & Major Partnerships
Discover how Nicox S.A. is reshaping eye care with cutting‑edge glaucoma, allergy, and inflammation therapies, backed by global partnerships and a robust pipeline.
2 minutes to read
Nicox S.A. Advances Ophthalmic Therapies Despite Market Volatility
Nicox S.A. continues to advance its ophthalmic therapies through innovative treatments and strategic partnerships, despite market fluctuations.
2 minutes to read
Nicox S.A. Advances Ophthalmic Therapies with Innovative Pipeline and Strategic Partnerships
Nicox S.A. is a French biotechnology company focused on researching and developing innovative ophthalmic therapies for various eye diseases, with a diverse product pipeline and collaborations with major pharmaceutical companies.
2 minutes to read